Long-Term Success With a TDM-1 Biosimilar in Recurrent HER2-Positive Breast Cancer With Multisite Metastases: A...

Area of Science:

• Oncology
• Pharmacology
• Medical Case Reports

Background:

• Advanced HER2-positive breast cancer often presents with widespread metastasis, posing significant treatment challenges.
• Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate used for HER2-positive breast cancer.
• Management of recurrent and metastatic breast cancer requires multimodal therapeutic strategies.

Observation:

• A 54-year-old female with recurrent, multi-site metastatic breast cancer (brain, liver, lungs, bones) received sequential therapies including trastuzumab, paclitaxel, radiation, and oral agents.
• Following brain metastasis diagnosis, whole-brain radiation therapy was administered, followed by trastuzumab emtansine (T-DM1) biosimilar therapy.
• The patient received over 30 cycles of T-DM1 biosimilar, maintaining a good quality of life.

Findings:

• The patient achieved a stable disease condition for 7.5 years post-recurrence.
• Trastuzumab emtansine (T-DM1) biosimilar demonstrated long-term efficacy and a satisfactory safety profile in this metastatic breast cancer case.
• This case illustrates the potential of T-DM1 biosimilar in managing advanced, recurrent HER2-positive breast cancer with multiple metastases.

Implications:

• This case report provides valuable insights into the long-term management of complex metastatic breast cancer cases.
• The findings support the role of T-DM1 biosimilar as a viable targeted therapy option for HER2-positive breast cancer with extensive metastasis.
• Further research into T-DM1 and its biosimilars in advanced breast cancer is warranted to optimize patient outcomes.